Skip to content
Biodatica
Start free

Eli Lilly and Company

Phoenix, Arizona

OncologyFiled/ApprovedListed · LLY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase III trial registered: A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

1w agoTrial registeredJul 7, 2026Source filing (opens the source filing in a new tab)

Momentum

96no change

Momentum 96 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE3 registered

    May 22, 2026

    Alzheimer Disease, Dementia, Plaque, Amyloid · RECRUITING · sponsor: Eli Lilly and Company · A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

    ClinicalTrials.gov · NCT07602582 (opens the source filing in a new tab)

  2. Trial

    PHASE4 registered

    Mar 19, 2025

    Psoriasis, Overweight or Obesity · RECRUITING · sponsor: Eli Lilly and Company · A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

    ClinicalTrials.gov · NCT06857942 (opens the source filing in a new tab)

  3. Trial

    PHASE3 registered

    Jul 10, 2023

    Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea · COMPLETED · sponsor: Eli Lilly and Company · A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

    ClinicalTrials.gov · NCT05929066 (opens the source filing in a new tab)

  4. Trial

    PHASE2 registered

    Nov 23, 2020

    Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Cognitive Impairment · COMPLETED · sponsor: Eli Lilly and Company · A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)

    ClinicalTrials.gov · NCT04640077 (opens the source filing in a new tab)

  5. Trial

    PHASE1/PHASE2 registered

    Jan 22, 2020

    Desmoplastic Small Round Cell Tumor · COMPLETED · sponsor: Eli Lilly and Company · CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

    ClinicalTrials.gov · NCT04145349 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources